The inquiry stems from the company's August 2023 financial report, where CVS revised its diluted earnings-per-share guidance downward to a range of $6.53 to $6.75. At the time, the corporation reported a $1.4 billion decline in operating income, a 30.7% drop attributed largely to struggles within its Health Care Benefits segment. This fiscal shift coincided with a pending securities class action lawsuit alleging that executives failed to disclose material information to investors.

Kahn Swick & Foti, which specializes in securities litigation, is now reviewing whether internal corporate governance failed to protect shareholder interests. The firm is inviting long-term CVS shareholders to discuss their legal standing and potential rights as the investigation proceeds. Interested parties may contact managing partner Lewis Kahn or visit the firm’s dedicated case portal for further guidance.